<html>
 <body>
  <div class="col-md-12" id="content" style="">
   <div class="hidden" data-drupal-messages-fallback="">
   </div>
   <div class="widget block" id="block-medsites-page-title">
    <h1>
     <span property="schema:name">
      Approach to CKD
     </span>
    </h1>
   </div>
   <div class="widget block" id="block-medsites-content">
    <article about="/commodorecompendium/approach-ckd" data-history-node-id="2975" role="article" typeof="schema:WebPage">
     <div>
      <div class="field field--name-body field--type-text-with-summary field--label-hidden field__item" property="schema:text">
       <div class="WordSection1">
        <div style="border-bottom:solid windowtext 1.0pt; border-top:double windowtext 1.5pt; border-left:none; border-right:none; padding:1.0pt 0in 0in 0in">
         <p style="border:none; padding:0in">
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <b>
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 Approach to Chronic Kidney Disease – Taylor Riggs
                </span>
               </span>
              </b>
             </span>
            </span>
           </span>
          </span>
         </p>
        </div>
        <p>
        </p>
        <p>
         <span style="page:WordSection1">
          <span style="font-size:11pt">
           <span style="line-height:normal">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               Background
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </p>
        <ul>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Decreased
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  kidney function or one or more markers of kidney damage for
                  <b>
                   3 or more months
                  </b>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                GFR
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  < 60; Staging helps risk-stratify pts likely to progress or develop complications of CKD
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
        </ul>
       </div>
       <div class="WordSection2">
        <ul>
         <li style="list-style-type:none">
          <ul style="list-style-type:circle">
           <li>
            <span style="page:WordSection2">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="background:white">
                  <span style="font-family:Palatino">
                   <span style="color:black">
                    CKD IIIa: eGFR 45-60
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection2">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="background:white">
                  <span style="font-family:Palatino">
                   <span style="color:black">
                    CKD IIIb: eGFR 30-44
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection2">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="background:white">
                  <span style="font-family:Palatino">
                   <span style="color:black">
                    CKD IV: eGFR 15-30
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection2">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="background:white">
                  <span style="font-family:Palatino">
                   <span style="color:black">
                    CKD V: eGFR < 15
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
          </ul>
         </li>
        </ul>
       </div>
       <p>
       </p>
       <div class="WordSection3">
        <ul>
         <li>
          <span style="page:WordSection3">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Markers
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  of kidney damage
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
          <ul style="list-style-type:circle">
           <li>
            <span style="page:WordSection3">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="background:white">
                  <span style="font-family:Palatino">
                   <span style="color:black">
                    Albuminuria (albumin:creatinine > 300mg/g or urine protein:creatinine > 500mg/g)
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection3">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="background:white">
                  <span style="font-family:Palatino">
                   <span style="color:black">
                    Urine sediment: RBC cases, WBC casts, oval fat bodies or fatty casts, granular casts
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection3">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="background:white">
                  <span style="font-family:Palatino">
                   <span style="color:black">
                    Electrolytes or other abnormalities due to tubular disorders
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection3">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="background:white">
                  <span style="font-family:Palatino">
                   <span style="color:black">
                    Abnormalities on histology (glomerular, vascular or cystic disease, TIN)
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection3">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="background:white">
                  <span style="font-family:Palatino">
                   <span style="color:black">
                    Structural abnormalities: (cysts, hydronephrosis, scarring, masses, renal artery stenosis)
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection3">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="background:white">
                  <span style="font-family:Palatino">
                   <span style="color:black">
                    History of kidney transplant (rejection, drug toxicity 2/2 calcineurin inhibitors, BK virus nephropathy, recurrent disease leading to transplant)
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
          </ul>
         </li>
         <li>
          <span style="page:WordSection3">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Refer
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  to AKI section for a detailed list of etiologies
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
        </ul>
        <p>
        </p>
        <p>
         <span style="page:WordSection3">
          <span style="font-size:11pt">
           <span style="line-height:normal">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               When to refer to nephrology clinic
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </p>
        <ul>
         <li>
          <span style="page:WordSection3">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                eGFR
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  < 30
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection3">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Persistent
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  urine albumin/creatinine ratio > 300 mg/g
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection3">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Urine protein/creatinine ratio greater than 500 mg/g
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection3">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Rapid
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  loss of kidney function (> 30% decline over 4 months)
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection3">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  Hematuria not 2/2 urologic condition or RBC casts
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection3">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Inability
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  to identify presumed cause of renal dysfunction
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection3">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Difficult
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  to manage complications (hyperkalemia, anemia, bone-mineral disease, HTN)
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection3">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Confirmed
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  or presumed hereditary kidney disease (PCKD suspected)
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
        </ul>
        <p style="margin-left:72px">
        </p>
        <p>
         <span style="page:WordSection3">
          <span style="font-size:11pt">
           <span style="line-height:normal">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               Albuminuria
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </p>
        <ul>
         <li>
          <span style="page:WordSection3">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Microalbuminuria
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  : 30-300 mg/day
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection3">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Macroalbuminuria
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  : > 300 mg/day (UA typically only detects these pts)
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
          <ul style="list-style-type:circle">
           <li>
            <span style="page:WordSection3">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="background:white">
                  <span style="font-family:Palatino">
                   <span style="color:black">
                    In patients with albuminuria found on UA, confirm albuminuria with 2 repeat tests over 3-6 months. Early morning void sample is best. Ensure patient does not have UTI, fever, recent IV contrast, hematuria, or alkaline urine.
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection3">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="background:white">
                  <span style="font-family:Palatino">
                   <span style="color:black">
                    After confirmation, monitor annually.
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection3">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="background:white">
                  <span style="font-family:Palatino">
                   <span style="color:black">
                    For patients with CKD or DM but without albuminuria, monitor annually for development of albuminuria
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
          </ul>
         </li>
         <li>
          <span style="page:WordSection3">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Treatment
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  : reducing proteinuria can slow the progression of renal disease
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
          <ul style="list-style-type:circle">
           <li>
            <span style="page:WordSection3">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="background:white">
                  <span style="font-family:Palatino">
                   <span style="color:black">
                    ACEi/ARBs: reduce intraglomerular pressure, thereby reducing proteinuria
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection3">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="background:white">
                  <span style="font-family:Palatino">
                   <span style="color:black">
                    Work over weeks to months. Not as rapid as anti-HTN effect.
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection3">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="background:white">
                  <span style="font-family:Palatino">
                   <span style="color:black">
                    Goal is to titrate ACEi/ARB to BP < 130/90
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection3">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="background:white">
                  <span style="font-family:Palatino">
                   <span style="color:black">
                    Most effective when used in conjunction with low Na diet (<2g/d) +/- diuretics
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
          </ul>
         </li>
         <li>
          <span style="page:WordSection3">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Can
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  add other anti-hypertensives to achieve goal BP if ACEi/ARB alone not able to be tolerated due to side effects (e.g. hyperkalemia)
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
        </ul>
        <p>
        </p>
        <p>
         <span style="page:WordSection3">
          <span style="font-size:11pt">
           <span style="line-height:normal">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               Metabolic acidosis
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </p>
        <ul>
         <li>
          <span style="page:WordSection3">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Goal
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  bicarbonate: 23-30
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection3">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Can
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  calculate bicarbonate deficit (MDcalc has calculator) and use that to estimate dose
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection3">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  If
                 </span>
                </span>
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                bicarb
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  < 22, consider starting:
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
          <ul style="list-style-type:circle">
           <li>
            <span style="page:WordSection3">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="background:white">
                  <span style="font-family:Palatino">
                   <span style="color:black">
                    Sodium bicarb 650 mg TID (8mEq bicarb per 650mg tablet). Can titrate up to 5850mg/day (70 mEq or 3 tabs TID)
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection3">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="background:white">
                  <span style="font-family:Palatino">
                   <span style="color:black">
                    Sodium citrate (bicitra): 1mL = 1 mEq
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection3">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="background:white">
                  <span style="font-family:Palatino">
                   <span style="color:black">
                    Baking soda: 1 teaspoon = 59 mEq HCO3 (often well-tolerated by patient compared to bicitra in terms of taste)
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
          </ul>
         </li>
        </ul>
       </div>
       <p>
       </p>
       <p>
        <span style="font-size:11pt">
         <span style="line-height:normal">
          <span style="font-family:Calibri,sans-serif">
           <span style="font-size:12.0pt">
            <span style="font-family:Palatino">
             HTN in CKD
            </span>
           </span>
          </span>
         </span>
        </span>
       </p>
       <ul>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Goal
             </span>
            </span>
            <span style="font-size:12.0pt">
             <span style="background:white">
              <span style="font-family:Palatino">
               <span style="color:black">
                BP < 130/80
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              CKD
             </span>
            </span>
            <span style="font-size:12.0pt">
             <span style="background:white">
              <span style="font-family:Palatino">
               <span style="color:black">
                stage 1 or 2 without albuminuria or DM:
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
         <ul style="list-style-type:circle">
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  Usual first line BP medications (ACEi/ARB, CCB, or HCTZ)
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
         </ul>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              CKD
             </span>
            </span>
            <span style="font-size:12.0pt">
             <span style="background:white">
              <span style="font-family:Palatino">
               <span style="color:black">
                stage 3 or greater
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
         <ul style="list-style-type:circle">
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  ACEi or ARB is first line
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  Can add diuretics to ACEi/ARB for adjunctive therapy in CKD 4-5
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  HCTZ not effective with eGFR < 30
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  Low sodium diet effective in volume and BP control
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
         </ul>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Consider
             </span>
            </span>
            <span style="font-size:12.0pt">
             <span style="background:white">
              <span style="font-family:Palatino">
               <span style="color:black">
                stopping ACEi/ARB if:
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
         <ul style="list-style-type:circle">
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  GFR declines >30% over 4 months and consider evaluation for renal artery stenosis with Duplex Doppler renal u/s vs CTA or MRA as initial screening
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  K > 5.5 despite efforts to decrease potassium (i.e. low K diet, optimizing dose of diuretics, adding K-binders)
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  If patient has an AKI on CKD, especially if pre-renal
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
         </ul>
        </li>
       </ul>
       <p>
       </p>
       <p>
        <span style="font-size:11pt">
         <span style="line-height:normal">
          <span style="font-family:Calibri,sans-serif">
           <span style="font-size:12.0pt">
            <span style="font-family:Palatino">
             Anemia in CKD
            </span>
           </span>
          </span>
         </span>
        </span>
       </p>
       <ul>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Etiology
             </span>
            </span>
            <span style="font-size:12.0pt">
             <span style="background:white">
              <span style="font-family:Palatino">
               <span style="color:black">
                : reduced EPO, chronic inflammation, uremic platelets/platelet dysfunction, loss of blood in dialysis circuit
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Indications
             </span>
            </span>
            <span style="font-size:12.0pt">
             <span style="background:white">
              <span style="font-family:Palatino">
               <span style="color:black">
                for iron supplementation in non-dialysis patients:
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
         <ul style="list-style-type:circle">
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  ALL patients with TSAT <20% and ferritin <100 ng/mL
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  Patients with Hb <13 and TSAT <30% and ferritin <500 ng/mL
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  Can consider oral iron supplementation unless severe anemia or iron deficiency
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  PO Iron dosing: New evidence shows that every other day oral iron leads to increased absorption and efficacy and decreased side effects
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
           <ul>
            <li style="list-style-type:none">
             <ul style="list-style-type:disc">
              <li>
               <span style="font-size:11pt">
                <span style="line-height:normal">
                 <span style="font-family:Calibri,sans-serif">
                  <span style="font-size:12.0pt">
                   <span style="font-family:Palatino">
                    <span style="color:black">
                     Ferrous sulfate 325mg (65mg elemental iron) every other day
                    </span>
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </li>
              <li>
               <span style="font-size:11pt">
                <span style="line-height:normal">
                 <span style="font-family:Calibri,sans-serif">
                  <span style="font-size:12.0pt">
                   <span style="font-family:Palatino">
                    <span style="color:black">
                     Reassess iron levels in 1-3 mos; if not appropriately
                    </span>
                   </span>
                  </span>
                  <span style="font-size:12.0pt">
                   <span style='font-family:"Times New Roman",serif'>
                    <span style="color:black">
                     ↑
                    </span>
                   </span>
                  </span>
                  <span style="font-size:12.0pt">
                   <span style="font-family:Palatino">
                    <span style="color:black">
                     , consider IV iron repletion
                    </span>
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </li>
             </ul>
            </li>
           </ul>
          </li>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  IV Fe dosing: 1000 mg IV, either via 1 dose or multiple doses depending on formulation
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
           <ul>
            <li style="list-style-type:none">
             <ul style="list-style-type:disc">
              <li>
               <span style="font-size:11pt">
                <span style="line-height:normal">
                 <span style="font-family:Calibri,sans-serif">
                  <span style="font-size:12.0pt">
                   <span style="font-family:Palatino">
                    <span style="color:black">
                     Ferric gluconate: max dose 250 mg over 1 hr, dosed weekly for 3-4 doses
                    </span>
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </li>
              <li>
               <span style="font-size:11pt">
                <span style="line-height:normal">
                 <span style="font-family:Calibri,sans-serif">
                  <span style="font-size:12.0pt">
                   <span style="font-family:Palatino">
                    <span style="color:black">
                     Iron dextran: 1000
                    </span>
                   </span>
                  </span>
                  <span style="font-size:12.0pt">
                   <span style="background:white">
                    <span style="font-family:Palatino">
                     <span style="color:#232323">
                      mg in a single dose, infused over one hour (less preferred due to
                     </span>
                    </span>
                   </span>
                  </span>
                  <span style="font-size:12.0pt">
                   <span style="font-family:Palatino">
                    <span style="color:#181817">
                     higher risk of allergic reactions; requires te
                    </span>
                   </span>
                  </span>
                  <span style="font-size:12.0pt">
                   <span style="font-family:Palatino">
                    <span style="color:black">
                     s
                    </span>
                   </span>
                  </span>
                  <span style="font-size:12.0pt">
                   <span style="font-family:Palatino">
                    <span style="color:#181817">
                     t dose 5 min prior)
                    </span>
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </li>
             </ul>
            </li>
           </ul>
          </li>
         </ul>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Dialysis
             </span>
            </span>
            <span style="font-size:12.0pt">
             <span style="background:white">
              <span style="font-family:Palatino">
               <span style="color:black">
                patients:
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
         <ul style="list-style-type:circle">
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  IV Iron preferred method of repletion for HD patients with
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
           <ul>
            <li style="list-style-type:none">
             <ul style="list-style-type:disc">
              <li>
               <span style="font-size:11pt">
                <span style="line-height:normal">
                 <span style="font-family:Calibri,sans-serif">
                  <span style="font-size:12.0pt">
                   <span style="font-family:Palatino">
                    <span style="color:black">
                     TSAT < 20% and ferritin < 200
                    </span>
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </li>
              <li>
               <span style="font-size:11pt">
                <span style="line-height:normal">
                 <span style="font-family:Calibri,sans-serif">
                  <span style="font-size:12.0pt">
                   <span style="font-family:Palatino">
                    <span style="color:black">
                     TSAT <30
                    </span>
                   </span>
                  </span>
                  <span style="font-size:12.0pt">
                   <span style="font-family:Palatino">
                    <span style="color:#181817">
                     % and ferritin <500 AND with Hb < 10 OR are on EPO
                    </span>
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </li>
             </ul>
            </li>
           </ul>
          </li>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  Dosing: usually administered at HD sessions
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
           <ul>
            <li style="list-style-type:none">
             <ul style="list-style-type:disc">
              <li>
               <span style="font-size:11pt">
                <span style="line-height:normal">
                 <span style="font-family:Calibri,sans-serif">
                  <span style="font-size:12.0pt">
                   <span style="font-family:Palatino">
                    <span style="color:black">
                     125 mg ferric gluconate at consecutive HD sessions x 8 doses
                    </span>
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </li>
              <li>
               <span style="font-size:11pt">
                <span style="line-height:normal">
                 <span style="font-family:Calibri,sans-serif">
                  <span style="font-size:12.0pt">
                   <span style="font-family:Palatino">
                    <span style="color:black">
                     100 mg iron sucrose at consecutive HD sessions x 10 doses
                    </span>
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </li>
              <li>
               <span style="font-size:11pt">
                <span style="line-height:normal">
                 <span style="font-family:Calibri,sans-serif">
                  <span style="font-size:12.0pt">
                   <span style="font-family:Palatino">
                    <span style="color:black">
                     Ferumoxytol 510mg at the end of two HD sessions 1-4 weeks apart
                    </span>
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </li>
             </ul>
            </li>
           </ul>
          </li>
         </ul>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Indications
             </span>
            </span>
            <span style="font-size:12.0pt">
             <span style="background:white">
              <span style="font-family:Palatino">
               <span style="color:black">
                for EPO
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
         <ul style="list-style-type:circle">
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  Pts w/ Hb <10 who are not iron deficient or who’s anemia persists despite adequate iron repletion
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
         </ul>
        </li>
       </ul>
       <p style="margin-left:37px">
       </p>
       <p>
        <span style="font-size:11pt">
         <span style="line-height:normal">
          <span style="font-family:Calibri,sans-serif">
           <span style="font-size:12.0pt">
            <span style="font-family:Palatino">
             Hyperkalemia (Goal K < 5.5)
            </span>
           </span>
          </span>
         </span>
        </span>
       </p>
       <ul>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Generally
             </span>
            </span>
            <span style="font-size:12.0pt">
             <span style="background:white">
              <span style="font-family:Palatino">
               <span style="color:black">
                , only develops in patients who are oliguric or with other problems, such as high K diet or hypoaldosteronism (due to ACEi/ARB)
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
         <ul style="list-style-type:circle">
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  Low K diet (< 40-70 mEq/day or 1500-2700 mg/day)
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  Add loop diuretics if hypertensive or hypervolemic; Can use thiazide if GFR > 30
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  GI cation exchangers: work within hours
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
           <ul>
            <li style="list-style-type:none">
             <ul style="list-style-type:disc">
              <li>
               <span style="font-size:11pt">
                <span style="line-height:normal">
                 <span style="font-family:Calibri,sans-serif">
                  <span style="font-size:12.0pt">
                   <span style="font-family:Palatino">
                    <span style="color:black">
                     Patiromer (Veltassa): binds K in colon in exchange for calcium
                    </span>
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </li>
              <li>
               <span style="font-size:11pt">
                <span style="line-height:normal">
                 <span style="font-family:Calibri,sans-serif">
                  <span style="font-size:12.0pt">
                   <span style="font-family:Palatino">
                    <span style="color:black">
                     Sodium zirconium cyclosilicate (Lokelma): binds K throughout intestine in exchange for sodium and H
                     <sup>
                      +
                     </sup>
                    </span>
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </li>
              <li>
               <span style="font-size:11pt">
                <span style="line-height:normal">
                 <span style="font-family:Calibri,sans-serif">
                  <span style="font-size:12.0pt">
                   <span style="font-family:Palatino">
                    <span style="color:black">
                     Need nephrology
                    </span>
                   </span>
                  </span>
                  <span style="font-size:12.0pt">
                   <span style="font-family:Palatino">
                    <span style="color:black">
                     attending approval for Lokelma
                    </span>
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </li>
             </ul>
            </li>
           </ul>
          </li>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  Do not use Kayexelate as chronic therapy
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  Ensure acidosis is treated due to resulting extracellular K
                  <sup>
                   +
                  </sup>
                  shift (see next section)
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  Consider discontinuing ACEi/ARB if K persistently > 5.5
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
         </ul>
        </li>
       </ul>
       <p>
       </p>
       <p>
        <span style="font-size:11pt">
         <span style="line-height:normal">
          <span style="font-family:Calibri,sans-serif">
           <span style="font-size:12.0pt">
            <span style="font-family:Palatino">
             Mineral bone disease in ESRD
            </span>
           </span>
          </span>
         </span>
        </span>
       </p>
       <ul>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="background:white">
              <span style="font-family:Palatino">
               <span style="color:black">
                Ca goal: < 9.5. Avoid supplementation in mild or asymptomatic hypocalcemia
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="background:white">
              <span style="font-family:Palatino">
               <span style="color:black">
                Vit D25 goal: > 20. Replete as in normal population
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Phos
             </span>
            </span>
            <span style="font-size:12.0pt">
             <span style="background:white">
              <span style="font-family:Palatino">
               <span style="color:black">
                goal: < 5.5. Start phosphate binders (sevelamer or noncalcium-based binders typically preferred) with goal Phos 3.5-5.5
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
         <ul style="list-style-type:circle">
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  Sevelamer: use lowest dose effective to achieve Phos < 5.5
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
           <ul>
            <li style="list-style-type:none">
             <ul style="list-style-type:disc">
              <li>
               <span style="font-size:11pt">
                <span style="line-height:normal">
                 <span style="font-family:Calibri,sans-serif">
                  <span style="font-size:12.0pt">
                   <span style="font-family:Palatino">
                    <span style="color:black">
                     Phos 5.5-7.5: initial dose 800 TID with meals
                    </span>
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </li>
              <li>
               <span style="font-size:11pt">
                <span style="line-height:normal">
                 <span style="font-family:Calibri,sans-serif">
                  <span style="font-size:12.0pt">
                   <span style="font-family:Palatino">
                    <span style="color:black">
                     Phos 7.5-9.0: initial dose 1200-1600 TID with meals
                    </span>
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </li>
              <li>
               <span style="font-size:11pt">
                <span style="line-height:normal">
                 <span style="font-family:Calibri,sans-serif">
                  <span style="font-size:12.0pt">
                   <span style="font-family:Palatino">
                    <span style="color:black">
                     Phos > 9: initial dose 1600 TID
                    </span>
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </li>
              <li>
               <span style="font-size:11pt">
                <span style="line-height:normal">
                 <span style="font-family:Calibri,sans-serif">
                  <span style="font-size:12.0pt">
                   <span style="font-family:Palatino">
                    <span style="color:black">
                     Can titrate
                    </span>
                   </span>
                  </span>
                  <span style="font-size:12.0pt">
                   <span style="font-family:Palatino">
                    <span style="color:black">
                     dosing by 400 to 800 mg per meal at 2 week intervals
                    </span>
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </li>
             </ul>
            </li>
           </ul>
          </li>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  Restrict dietary phos to 900 mg/day
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
         </ul>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              PTH
             </span>
            </span>
            <span style="font-size:12.0pt">
             <span style="background:white">
              <span style="font-family:Palatino">
               <span style="color:black">
                goal: 2-9 x ULN, although exact goal unknown in assessing renal bone disease. Treatment involves calcimemetics, calcitriol, and synthetic vitamin D analogues.
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
       </ul>
       <p>
       </p>
       <p>
        <span style="font-size:11pt">
         <span style="line-height:normal">
          <span style="font-family:Calibri,sans-serif">
           <span style="font-size:12.0pt">
            <span style="font-family:Palatino">
             Diabetes in CKD
            </span>
           </span>
          </span>
         </span>
        </span>
       </p>
       <ul>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              A1c
             </span>
            </span>
            <span style="font-size:12.0pt">
             <span style="background:white">
              <span style="font-family:Palatino">
               <span style="color:black">
                goal:
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
         <ul style="list-style-type:circle">
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  < 7% in patients with long lifespan, few comorbidities, and minimal hypoglycemia
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  < 8% in patients with multiple comorbidities and frequent/high risk for hypoglycemia
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
         </ul>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Treatment
             </span>
            </span>
            <span style="font-size:12.0pt">
             <span style="background:white">
              <span style="font-family:Palatino">
               <span style="color:black">
                :
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
         <ul style="list-style-type:circle">
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  Metformin remains first-line but should be dose-reduced based on eGFR
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
           <ul>
            <li style="list-style-type:none">
             <ul style="list-style-type:disc">
              <li>
               <span style="font-size:11pt">
                <span style="line-height:normal">
                 <span style="font-family:Calibri,sans-serif">
                  <span style="font-size:12.0pt">
                   <span style="font-family:Palatino">
                    <span style="color:black">
                     eGFR > 45: Maximum daily dose of 2000mg/day (1000mg bid)
                    </span>
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </li>
              <li>
               <span style="font-size:11pt">
                <span style="line-height:normal">
                 <span style="font-family:Calibri,sans-serif">
                  <span style="font-size:12.0pt">
                   <span style="font-family:Palatino">
                    <span style="color:black">
                     eGFR < 45: Reduce max daily dose to 1000mg/day (500mg bid)
                    </span>
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </li>
              <li>
               <span style="font-size:11pt">
                <span style="line-height:normal">
                 <span style="font-family:Calibri,sans-serif">
                  <span style="font-size:12.0pt">
                   <span style="font-family:Palatino">
                    <span style="color:black">
                     eGFR < 30: Discontinue
                    </span>
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </li>
             </ul>
            </li>
           </ul>
          </li>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  SGLT-2 inhibitors for patients with eGFR > 30 reduces progression to ESRD and death from renal or cardiovascular causes
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
         </ul>
        </li>
       </ul>
       <p style="margin-left:72px">
       </p>
       <p>
        <span style="font-size:11pt">
         <span style="line-height:normal">
          <span style="font-family:Calibri,sans-serif">
           <span style="font-size:12.0pt">
            <span style="font-family:Palatino">
             Dialysis initiation
            </span>
           </span>
          </span>
         </span>
        </span>
       </p>
       <ul>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Dialysis
             </span>
            </span>
            <span style="font-size:12.0pt">
             <span style="background:white">
              <span style="font-family:Palatino">
               <span style="color:black">
                education is usually started once patients are in CKD IV with eGFR 15-30, so earlier referral to nephrology may be helpful in patients with eGFR 30-45 who you think may be heading towards eGFR <30
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Late
             </span>
            </span>
            <span style="font-size:12.0pt">
             <span style="background:white">
              <span style="font-family:Palatino">
               <span style="color:black">
                referral to a nephrologist (ie, less than three months before the start of dialysis therapy) is associated with higher mortality after the initiation of dialysis
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
       </ul>
      </div>
     </div>
    </article>
   </div>
  </div>
 </body>
</html>